Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer
An erratum to this article was published (JAMA Netw Open, 5 Feb 2024 ↗)
Authors' conclusion
The findings of this study suggest that baseline FBM is an independent factor for VF progression in patients with EBC treated with adjuvant AIs and denosumab.
Study context
- Population
- Postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitors (AIs) with denosumab (60 mg every 6 months), Breast Unit of the ASST Spedali Civili of Brescia, September 2014 to June 2018
- Participants
- 237 women
- Outcome
- VF progression (new or worsening of preexisting VFs) between study entry and 18 months, assessed by DXA
- Follow-up
- 18 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Association with VF progression (multivariable analysis)
Odds ratio (95% CI)P value
Percentage of FBM
5.41(1.49–19.59)
P = 0.01FRAX score
3.95(1.09–14.39)
P = 0.04- Vertebral fracture (VF) progression among 237 enrolled patients
- 17 (4.4%)
Observational data: associations, not effects.
Further findings
Factors associated with VF progression, univariable analysis
| OR (95% CI) | P value | ||
|---|---|---|---|
| History of clinical fractures | 3.22 (1.19–8.74) | P = 0.02 | |
| FRAX score for major fractures | 4.42 (1.23–13.79) | P = 0.04 | |
| Percentage of FBM | 6.04 (1.69–21.63) | P = 0.006 | |
| Android fat | 9.58 (1.17–78.21) | P = 0.04 | |
| Appendicular lean mass index-FBM ratioInverse association | 0.25 (0.08–0.82) | P = 0.02 | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer. JAMA Netw Open. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →